Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Chief Medical Officer | November 01, 2021 | November 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tango Therapeutics, Inc.
Report date November 01, 2021 · Filed November 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.91 · Expires 2031-11-01 | Direct | 350,000 |
Reported balance
After 2021-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-01 · Grant · Acquired 350,000 · Balance 350,000 F1: This option shall vest and become exercisable over a four-year period, at a rate of 25% on October 18, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable over a four-year period, at a rate of 25% on October 18, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 20:15 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $12.91 | $0.00 |
DisclosureSEC source: 0000899243-21-042702 · doc4.xml · derivative · entry 1 Rudoltz Marc · CIK 0001890661 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, at a rate of 25% on October 18, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.